Information  X 
Enter a valid email address

ShieldTherapeutics Ord1.5P (STX)

Date Time Source Announcement
29 Apr 2022 7:00 am
RNS
Total Voting Rights Update
31 Mar 2022 3:50 pm
RNS
Block Listing Application
  3:50 pm
RNS
Block Listing 6 Monthly Return
21 Mar 2022 7:00 am
RNS
KYE Pharmaceuticals Files Accrufer? NDS in Canada
02 Mar 2022 1:30 pm
EQS
Shield Therapeutics (STX) - PBMs have bought in to Accrufer
25 Feb 2022 7:00 am
RNS
Investor Presentation
23 Feb 2022 2:06 pm
RNS
Second Price Monitoring Extn
  2:01 pm
RNS
Price Monitoring Extension
  11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
18 Feb 2022 2:06 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
17 Feb 2022 9:05 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Full Year Trading Update
04 Feb 2022 7:00 am
RNS
KOL Investor Event on Iron Deficiency
07 Jan 2022 7:00 am
RNS
Investor Presentation
05 Jan 2022 7:00 am
RNS
Licence Agreement in Canada for Accrufer?
30 Dec 2021 9:06 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
29 Dec 2021 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
16 Dec 2021 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Patient Access Expands for Accrufer?
07 Oct 2021 9:45 am
EQS
Shield Therapeutics (STX) Life Sciences Investor Forum research
30 Sep 2021 5:30 pm
RNS
Block Listing 6 Monthly Return
27 Sep 2021 7:00 am
RNS
Jose A. Menoyo Appointed as Chief Medical Officer
21 Sep 2021 7:00 am
RNS
Investor presentation
23 Aug 2021 7:00 am
RNS
PDMR Transaction Notification
20 Aug 2021 11:08 am
EQS
Shield Therapeutics (STX) - Focused on US market penetration
17 Aug 2021 7:00 am
RNS
Half-year Report
12 Aug 2021 7:25 am
EQS
Hardman & Co Video Event | Shield Therapeutics plc - Investor Forum
  7:00 am
RNS
Licence agreement secured in Republic of Korea
11 Aug 2021 7:00 am
RNS
Notice of Results
09 Aug 2021 7:00 am
RNS
AEGIS-CKD study results published in AJKD
04 Aug 2021 4:41 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  2:05 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
24 Jun 2021 7:00 am
RNS
US launch of Accrufer? confirmed for July 1, 2021
23 Jun 2021 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
21 Jun 2021 1:35 pm
RNS
Investor presentation
18 Jun 2021 7:00 am
RNS
Directorate Change
17 Jun 2021 2:30 pm
RNS
Results of 2021 Annual General Meeting
15 Jun 2021 6:15 pm
RNS
Grant of share options to the CEO
28 May 2021 7:00 am
RNS
Appointment of new Chief Executive Officer
  7:00 am
RNS
Total Voting Rights
26 May 2021 10:35 am
EQS
Shield Therapeutics (STX): Accrufer launch on schedule
21 May 2021 7:00 am
RNS
US update
18 May 2021 7:00 am
RNS
AEGIS-H2H study results published in IBD
17 May 2021 7:00 am
RNS
Commencement of trading on the OTCQX Best Market
13 May 2021 3:00 pm
RNS
2020 Annual Report and 2021 AGM Notice
10 May 2021 7:00 am
RNS
Appointment of Two Non-Executive Directors
06 May 2021 1:44 pm
RNS
Total Voting Rights Update
29 Apr 2021 7:00 am
RNS
Preliminary Results
22 Apr 2021 7:00 am
RNS
Notice of Results
07 Apr 2021 9:33 am
RNS
Holding(s) in Company
  9:31 am
RNS
Holding(s) in Company
06 Apr 2021 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Holding(s) in Company
31 Mar 2021 3:01 pm
RNS
Total Voting Rights Update
  3:00 pm
RNS
Block Listing 6 Monthly Return
30 Mar 2021 7:00 am
RNS
Investor presentation
26 Mar 2021 7:00 am
RNS
Study demonstrates effectiveness of ferric maltol
24 Mar 2021 5:40 pm
RNS
Block Listing Application
23 Mar 2021 5:53 pm
RNS
Holding(s) in Company
  12:23 pm
RNS
Holding(s) in Company
22 Mar 2021 7:00 am
RNS
Shield appoints new Chief Financial Officer
18 Mar 2021 2:02 pm
RNS
Result of General Meeting & Open Offer
15 Mar 2021 5:21 pm
RNS
Holding(s) in Company
09 Mar 2021 7:00 am
RNS
Australia's TGA approves Feraccru
05 Mar 2021 4:54 pm
RNS
PDMR Transaction Notification
04 Mar 2021 6:17 pm
RNS
PDMR/PCA Transaction Notification
03 Mar 2021 1:40 pm
RNS
Investor Presentation
01 Mar 2021 7:00 am
RNS
Publication of Circular and Notice of GM
26 Feb 2021 4:09 pm
RNS
Successful completion of �25 million Fundraise
  12:30 pm
RNS
Total Voting Rights Update
  11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  9:30 am
RNS
Placing and Subscription to raise up to �25m
19 Feb 2021 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
02 Feb 2021 8:00 am
EQS
Shield Therapeutics (STX): Beefing up for the US opportunity
29 Jan 2021 2:38 pm
RNS
Shareholder loan facilities
  7:00 am
RNS
Total Voting Rights Update
21 Jan 2021 5:41 pm
RNS
Director/PDMR Shareholding
19 Jan 2021 2:20 pm
RNS
Director/PDMR Shareholding
15 Jan 2021 10:00 am
RNS
Investor presentation
  7:00 am
RNS
Business and trading update
14 Jan 2021 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
06 Jan 2021 7:15 am
EQS
Shield Therapeutics (STX): Reassessing the US opportunity
31 Dec 2020 7:00 am
RNS
Total Voting Rights Update
22 Dec 2020 10:06 am
RNS
Holding(s) in Company
21 Dec 2020 7:00 am
RNS
Investor Presentation
18 Dec 2020 5:21 pm
RNS
Grant of share options to the CEO
  5:15 pm
RNS
PDMR Exercise of Share Options
14 Dec 2020 7:00 am
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Investor Presentation
10 Dec 2020 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Update re US partnering discussions
30 Nov 2020 7:00 am
RNS
Holding(s) in Company
  7:00 am
RNS
Total Voting Rights Update
02 Nov 2020 7:00 am
RNS
Total Voting Rights Update
19 Oct 2020 7:00 am
RNS
Withdrawal of all oppositions by TEVA
30 Sep 2020 1:21 pm
RNS
Block Listing 6 Monthly Return
  1:20 pm
RNS
Total Voting Rights Update
18 Sep 2020 1:30 pm
EQS
Shield Therapeutics (STX): Optimism over US deal
16 Sep 2020 7:00 am
RNS
Half-year Report
14 Sep 2020 7:00 am
RNS
Notice of Results
28 Aug 2020 12:21 pm
RNS
Total Voting Rights Update
06 Aug 2020 2:21 pm
RNS
AEGIS-H2H study reanalysis
31 Jul 2020 7:00 am
RNS
Total Voting Rights update
16 Jul 2020 7:00 am
RNS
PT20 paper publication
30 Jun 2020 7:00 am
RNS
Total Voting Rights Update
26 Jun 2020 7:00 am
RNS
Appointment of Non-Executive Director
18 Jun 2020 3:18 pm
RNS
Results of 2020 Annual General Meeting
03 Jun 2020 7:00 am
RNS
Feraccru?/Accrufer? publications
29 May 2020 11:25 am
RNS
Total Voting Rights Update
28 May 2020 7:00 am
RNS
Investor presentations
26 May 2020 7:00 am
RNS
Appointment of Chairman
22 May 2020 4:15 pm
RNS
2019 Annual Report and 2020 AGM Notice
21 May 2020 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  7:00 am
RNS
Preliminary Results
19 May 2020 7:00 am
RNS
Notice of Results
11 May 2020 1:15 pm
EQS
Shield Therapeutics (STX): Reassuring trading update
01 May 2020 7:00 am
RNS
Business and trading update
30 Apr 2020 5:23 pm
RNS
Total Voting Rights Update
27 Apr 2020 7:00 am
RNS
Further re. Directorate Change
22 Apr 2020 7:00 am
RNS
Directorate Change
26 Mar 2020 4:42 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension
20 Mar 2020 11:36 am
RNS
Holding(s) in Company
17 Mar 2020 2:06 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
  7:00 am
RNS
AEGIS-H2H study update
06 Mar 2020 7:00 am
RNS
Investor Presentation
02 Mar 2020 4:41 pm
RNS
Block Listing Application
21 Feb 2020 11:14 am
RNS
Holding(s) in Company
28 Jan 2020 12:15 pm
EQS
Shield Therapeutics (STX): Good demand for Feraccru in Europe
27 Jan 2020 7:00 am
RNS
Business and trading update
24 Jan 2020 7:00 am
RNS
Investor presentations
14 Jan 2020 7:15 am
EQS
Shield Therapeutics (STX): Taking on China
08 Jan 2020 7:00 am
RNS
China licence agreement for Feraccru/Accrufer
12 Dec 2019 5:30 pm
RNS
Eland Oil & Gas
29 Nov 2019 3:31 pm
RNS
Holding(s) in Company
25 Nov 2019 7:00 am
RNS
QCA Corporate Governance Code
30 Oct 2019 7:30 am
EQS
Shield Therapeutics (STX): More choice for clinicians and patients
22 Oct 2019 7:00 am
RNS
Positive results presented at UEG Week 2019
26 Sep 2019 7:00 am
RNS
Investor Presentation
02 Sep 2019 9:13 am
EQS
Shield Therapeutics (STX): FDA approval ushers in a new era for Shield
29 Aug 2019 7:00 am
RNS
Investor presentations
15 Aug 2019 10:17 am
RNS
Director/PDMR Shareholding
07 Aug 2019 7:00 am
RNS
Half-year Report
05 Aug 2019 11:22 am
EQS
Shield Therapeutics (STX) FDA approval opens door to major US opportunity
31 Jul 2019 1:21 pm
RNS
Notice of Results
26 Jul 2019 2:05 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
  7:00 am
RNS
FDA approves Feraccru? with a broad label
02 Jul 2019 12:00 pm
RNS
Additional Listing
13 Jun 2019 2:16 pm
RNS
Result of AGM
03 Jun 2019 7:00 am
RNS
Update on Legal Proceedings
13 May 2019 12:00 pm
EQS
Shield Therapeutics (STX): All in the execution
08 May 2019 7:00 am
RNS
Appointment of Joint Broker
02 May 2019 7:00 am
RNS
Investor presentation
01 May 2019 11:58 am
RNS
Additional Listing
30 Apr 2019 7:00 am
RNS
2018 Annual Report and 2019 AGM Notice
26 Apr 2019 6:05 pm
RNS
PDMR Acquisition of Shares
24 Apr 2019 7:00 am
RNS
Major extension to approval in Switzerland
17 Apr 2019 5:06 pm
RNS
Grant of share options
  5:01 pm
RNS
PDMR Acquisition of Shares and Additional Listing
  4:56 pm
RNS
PDMR Acquisition of Shares
11 Apr 2019 4:40 pm
RNS
Holding(s) in Company
08 Apr 2019 3:42 pm
RNS
Additional Listing
03 Apr 2019 7:00 am
RNS
Final Results
01 Apr 2019 5:44 pm
RNS
Additional Listing
  12:00 pm
RNS
Change of Adviser
27 Mar 2019 7:00 am
RNS
Notice of Results
14 Mar 2019 3:31 pm
RNS
Positive decision on Feraccru?'s process patent
04 Mar 2019 7:00 am
RNS
Positive results for Feraccru? in AEGIS-H2H study
29 Jan 2019 7:00 am
RNS
Positive results of AEGIS-CKD study
28 Jan 2019 7:15 am
EQS
Shield Therapeutics (STX): Cast-iron investment
24 Jan 2019 7:00 am
RNS
Business and trading update
23 Jan 2019 10:19 am
RNS
Investor presentations
22 Jan 2019 7:00 am
RNS
Appointment of Chairman
13 Dec 2018 7:00 am
RNS
US New Drug Application PDUFA date for Feraccru
05 Dec 2018 10:04 am
RNS
UK launch of Feraccru? by Norgine
03 Dec 2018 7:00 am
RNS
New Drug Application for Feraccru?
09 Nov 2018 3:46 pm
RNS
Holding(s) in Company
08 Nov 2018 6:21 pm
RNS
Holding(s) in Company
01 Oct 2018 1:54 pm
RNS
Notification Of Major Holdings
  7:00 am
RNS
Submission of an NDA for Feraccru? with the FDA
24 Sep 2018 1:06 pm
RNS
Director/PDMR Shareholding
  1:02 pm
RNS
Holding(s) in Company
19 Sep 2018 7:14 am
RNS
Licence for the commercialisation of Feraccru
  7:12 am
RNS
Interim Results
13 Sep 2018 7:00 am
RNS
AEGIS-H2H Completion of Recruitment
26 Jul 2018 7:00 am
RNS
Appointment of Non-Executive Director
23 Jul 2018 7:00 am
RNS
Business Update
09 Jul 2018 4:27 pm
RNS
Holdings in Company
  4:26 pm
RNS
Holdings in Company
28 Jun 2018 11:56 am
RNS
Result of AGM
  7:00 am
RNS
Data from real-world clinical use of Feraccru
14 Jun 2018 7:00 am
RNS
Positive top-line results from AEGIS-PAED PK study
05 Jun 2018 7:00 am
RNS
Directorate Change
  7:00 am
RNS
2017 Annual Report and 2018 AGM Notice
15 May 2018 6:21 pm
RNS
Grant of share options
04 May 2018 9:20 am
RNS
Holding(s) in Company
03 May 2018 5:26 pm
RNS
Holding(s) in Company
02 May 2018 11:00 am
RNS
Price Monitoring Extension
11 Apr 2018 7:00 am
RNS
Preliminary Results for the Year Ended 31 Dec 17
06 Apr 2018 7:00 am
RNS
Appointment of Non-Executive Director
  7:00 am
RNS
Results of Pre-Submission Meeting with FDA
27 Mar 2018 7:00 am
RNS
Broadening of Feraccru indication
16 Mar 2018 7:00 am
RNS
Update on the AEGIS-CKD study
23 Feb 2018 1:56 pm
RNS
Receives CHMP positive opinion on Feraccru?
22 Feb 2018 7:00 am
RNS
Business and Trading Update
05 Feb 2018 7:00 am
RNS
Top-line results from Feraccru Phase III study
29 Jan 2018 7:00 am
RNS
Notice of Results
25 Jan 2018 7:00 am
RNS
Grant of share options
10 Oct 2017 7:00 am
RNS
Completion of patient enrolment in Phase 3 study
05 Oct 2017 7:00 am
RNS
PDMR Acquisition of Shares
20 Sep 2017 7:00 am
RNS
Interim Report
14 Sep 2017 7:00 am
RNS
Board Change
06 Sep 2017 7:00 am
RNS
US Composition of Matter Patent Allowed
31 Aug 2017 7:00 am
RNS
Shield to Present at Baird Healthcare Conference
15 Aug 2017 7:00 am
RNS
Notice of Results
11 Jul 2017 2:59 pm
RNS
Grant of Share Options
10 Jul 2017 4:16 pm
RNS
Holding(s) in Company
06 Jul 2017 7:00 am
RNS
Feraccru licence agreement for Switzerland
05 Jul 2017 12:38 pm
RNS
Holding(s) in Company
03 Jul 2017 12:34 pm
RNS
Warrant Exercise and Expiry
28 Jun 2017 10:37 am
RNS
Holding(s) in Company
  8:00 am
RNS
Admission of New Ordinary Shares
22 Jun 2017 7:00 am
RNS
Biomarker data on ferric maltol in patients
15 Jun 2017 1:59 pm
RNS
Results of Fundraise
  7:00 am
RNS
Proposed Fundraise
13 Jun 2017 2:40 pm
RNS
Result of AGM
26 May 2017 7:00 am
RNS
Appointment of Joint Broker
28 Apr 2017 7:00 am
RNS
Annual Report, Accounts and AGM Notification
04 Apr 2017 7:00 am
RNS
Appointment of Chief Financial Officer
  7:00 am
RNS
Preliminary Results for the Year Ended 31 Dec 2016
13 Mar 2017 7:00 am
RNS
Notice of Results
  7:00 am
RNS
IP Portfolio Update
30 Jan 2017 10:50 am
RNS
Directorate and Secretarial Update
06 Jan 2017 7:00 am
RNS
Business Update
07 Nov 2016 7:00 am
RNS
Board Change
20 Sep 2016 7:00 am
RNS
Interim Results for six months ended 30 June 2016
13 Sep 2016 9:25 am
RNS
Grant of Share Awards
07 Sep 2016 7:37 am
RNS
Composition of Matter Patent Granted on Feraccru?
15 Aug 2016 12:22 pm
RNS
Notice of Results
04 Aug 2016 11:05 am
RNS
Result of AGM
01 Aug 2016 12:00 pm
RNS
Presenting at Canaccord Genuity Conference, Boston
30 Jun 2016 5:06 pm
RNS
2015 Annual Report and Accounts and Notice of AGM
14 Jun 2016 7:00 am
RNS
Maiden Preliminary Results for FY15
23 Mar 2016 7:00 am
RNS
Notice of results and change of accounting date
11 Mar 2016 7:00 am
RNS
Grant of Share Awards
26 Feb 2016 8:34 am
RNS
First Day of Dealings on AIM
  7:00 am
RNS
Feraccru? receives EU marketing authorisation

a d v e r t i s e m e n t